GEHC Stock Analysis: Buy, Sell, or Hold?
GEHC - GE HealthCare Technologies Inc. Common Stock
$68.77
-0.46 (-0.66%)
▼
5d:
-4.02%
30d:
-18.39%
90d:
-17.75%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 29, 2026
29d
Smart Money Accumulation
GEHC is down 5.9% this week, but smart money is accumulating calls. Top strike: $95 2026-04-17 with 1,460 OI. Call ratio: 62% View Scanner →
Strength: 4.1/10
Get Alerted When GEHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GEHC trading at deep discount. Market pricing in -6.9% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: GEHC trading at deep discount. Market pricing in -6.9% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$120.12
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$74.59
7.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GEHC is currently trading at $68.77, which is considered oversold relative to its 30-day fair value range of $70.06 to $81.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.4) compared to its historical average (15.4). Remarkably, the market is currently pricing in an annual earnings decline of 6.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GEHC is in a uptrend. The price is currently testing key support at $69.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $93.47 (+35.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GEHC is in a uptrend. The price is currently testing key support at $69.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $93.47 (+35.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$70.06 -
$81.17
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.0% below Wall St target ($93.47)
Fair Price Analysis
30-Day Fair Range
$70.06 -
$81.17
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$69.00
Resistance Level
$73.89
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.44
Wall Street Target
$93.47
(+35.0%)
Revenue Growth (YoY)
7.1%
Earnings Growth (YoY)
-17.7%
Profit Margin
10.1%
Valuation Discount vs History
-6.9% cheaper
PE vs Historical
12.4 vs 15.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.9%
(market-implied from PE analysis)
1-Year Target
$64.45
(-7%)
2-Year Target
$60.01
(-13%)
3-Year Target
$55.87
(-19%)
3-Yr Target (if PE normalizes)
(PE: 12→15)
$69.18
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 10.0%)
$165.95
(+140%)
Base:
(SPY PE: 12.4, Growth: 10.0%)
$92.14
(+33%)
Bear:
(PE: 10.6, Growth: 10.0%)
$78.32
(+13%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 15.31 | Current EPS (TTM): $4.55
Bull Case
$93.76
(+31%)
Analyst growth 22.4%, PE expands to 16.8
Base Case
$85.24
(+19%)
Market implied 22.4%, PE stable at 15.3
Bear Case
$47.36
(-34%)
Severe decline -20.0%, PE contracts to 13.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.4 to 15.4
Stabilization Target:
$85.73
(+23.8%)
PE Expansion Potential:
+23.8%
Share & Embed Analysis
Last updated: March 30, 2026 4:29 PM ET
Data refreshes hourly during market hours. Next update: 5:29 PM
Data refreshes hourly during market hours. Next update: 5:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GEHC showing a specific setup today?
Insider Activity (6 Months)
2
Buys
2
Sells
0
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-02-17
Ro Khanna
SELL
2026-02-06
Ro Khanna
BUY
2026-02-05
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 61 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
Advanced GEHC Option Strategies
Professional options setups generated by AI based on today's GEHC price and gamma walls.
